{"id":"NCT01696084","sponsor":"Jazz Pharmaceuticals","briefTitle":"Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia","officialTitle":"Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age With Untreated High Risk (Secondary) AML","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-12-13","primaryCompletion":"2015-12-31","completion":"2015-12-31","firstPosted":"2012-09-28","resultsPosted":"2017-10-02","lastUpdate":"2020-08-10"},"enrollment":309,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["High Risk Acute Myeloid Leukemia"],"interventions":[{"type":"DRUG","name":"CPX-351","otherNames":[]},{"type":"DRUG","name":"7+3 (cytarabine and daunorubicin)","otherNames":["cytarabine and daunorubicin"]}],"arms":[{"label":"Arm A (CPX-351)","type":"EXPERIMENTAL"},{"label":"Arm B (7+3)","type":"ACTIVE_COMPARATOR"}],"summary":"To confirm the efficacy of CPX-351 compared to 7+3 as first line therapy in elderly patients (60-75 yrs) with high risk (secondary) Acute Myeloid Leukemia. The primary efficacy endpoint will be overall survival.","primaryOutcome":{"measure":"Overall Survival","timeFrame":"From the date of randomization to death from any cause","effectByArm":[{"arm":"Arm A (CPX-351)","deltaMin":9.56,"sd":null},{"arm":"Arm B (7+3)","deltaMin":5.95,"sd":null}],"pValues":[]},"eligibility":{"minAge":"60 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":14},"locations":{"siteCount":43,"countries":["United States","Canada"]},"refs":{"pmids":["36289532","34256819","34171279","33724305","31760835","30024784","26660428"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":90,"n":153},"commonTop":["Febrile Neutropenia","Diarrhoea","Nausea","Oedema Peripheral","Constipation"]}}